ASH 2023 | The future of CLL therapy
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, provides his views on the future of chronic lymphocytic leukemia (CLL) treatment, highlighting the ongoing move from chemotherapy to immunotherapy and the unmet needs which remain in this disease area. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Well, I think we’re seeing more and more… we’ve already, well, we’ve already seen the move away from chemotherapy to targeted therapies, and that targeted therapy has really moved the whole field in CLL. But, of course, the unmet needs are the patients who become double-refractory to the BTK inhibitor and the BCL2 inhibitor, and of course, Richter’s transformation...
Well, I think we’re seeing more and more… we’ve already, well, we’ve already seen the move away from chemotherapy to targeted therapies, and that targeted therapy has really moved the whole field in CLL. But, of course, the unmet needs are the patients who become double-refractory to the BTK inhibitor and the BCL2 inhibitor, and of course, Richter’s transformation. I think in those spaces, I don’t see us going back to chemotherapy, so I think the immunotherapies in this field are really where we’re hoping the next major advances are really going to be in terms of the availability of products for our patients to be able to get into that space. And of course, we’ve just had the approval in CLL, at least in the US, for pirtobrutinib, we’re hoping that will follow soon in Europe. That gives us that next line of therapy for that double-refractory patient population. But I think immunotherapy what is going to be the next big move forward in CLL.
Read more...
Disclosures
Consultancy: AstraZeneca, AbbVie, Kite – A Gilead Company, Janssen Pharmaceuticals Inc., Novartis
Research Funding: AstraZeneca, Janssen Pharmaceuticals Inc.
Speakers Bureau: AbbVie, A Gilead Company, Janssen Pharmaceuticals Inc., Bristol Myers Squibb
